×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVS – novartis ag (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/13
08:13 pm
nvs
Novartis AGM Links Board Refresh And Dividend Growth To Future Returns [Yahoo! Finance]
Neutral
Report
Novartis AGM Links Board Refresh And Dividend Growth To Future Returns [Yahoo! Finance]
3/13
02:01 pm
nvs
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa [Yahoo! Finance]
Low
Report
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa [Yahoo! Finance]
3/13
09:29 am
nvs
Peanut Allergy Market Analysis Report 2025-2035: PALFORZIA and Xolair Approvals, Improved Diagnosis and Innovative Drug Delivery Platforms Drive Growth [Yahoo! Finance]
Low
Report
Peanut Allergy Market Analysis Report 2025-2035: PALFORZIA and Xolair Approvals, Improved Diagnosis and Innovative Drug Delivery Platforms Drive Growth [Yahoo! Finance]
3/11
08:04 pm
nvs
Lilly unveils $3 billion production expansion in China [Yahoo! Finance]
Low
Report
Lilly unveils $3 billion production expansion in China [Yahoo! Finance]
3/11
08:42 am
nvs
Novartis (NVS) was upgraded by Argus from "hold" to "buy". They now have a $180.00 price target on the stock.
Low
Report
Novartis (NVS) was upgraded by Argus from "hold" to "buy". They now have a $180.00 price target on the stock.
3/10
12:01 pm
nvs
Sandoz creates biosimilar unit to benefit from major patent cliff [Seeking Alpha]
Low
Report
Sandoz creates biosimilar unit to benefit from major patent cliff [Seeking Alpha]
3/10
09:45 am
nvs
Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board [Yahoo! Finance]
Low
Report
Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D., to Scientific Advisory Board [Yahoo! Finance]
3/7
07:03 pm
nvs
Novartis Advances Immunology And Oncology Plans As Valuation Gap Persists [Yahoo! Finance]
Low
Report
Novartis Advances Immunology And Oncology Plans As Valuation Gap Persists [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/12
02:44 pm
nvs
Form 144 NOVARTIS AG Filed by: Marshall Fiona
Low
Report
Form 144 NOVARTIS AG Filed by: Marshall Fiona
2/9
11:49 am
nvs
Form 144 NOVARTIS AG Filed by: Bulto Carulla Victor
Low
Report
Form 144 NOVARTIS AG Filed by: Bulto Carulla Victor
2/4
06:52 am
nvs
Form 6-K NOVARTIS AG For: Dec 31
Low
Report
Form 6-K NOVARTIS AG For: Dec 31
2/4
06:51 am
nvs
Form 6-K NOVARTIS AG For: Dec 31
Low
Report
Form 6-K NOVARTIS AG For: Dec 31
2/4
06:47 am
nvs
Form 20-F NOVARTIS AG For: Dec 31
Low
Report
Form 20-F NOVARTIS AG For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/4
BRIEF-Novartis has stock to cover production, distribution for now, monitoring India API changes [Reuters]
4.8%
7/17 The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On [The Motley Fool] 4.5%
5/23 Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency 3.6%
8/11 5 Reasons Novartis Shareholders Aren't Shaken [The Motley Fool] 3.4%
8/7 Glancy Prongay & Murray LLP Announces Investigation on Behalf of Novartis AG Investors (NVS) 2.7%
4/4 Novartis AG (NYSE: NVS) had its "buy" rating re-affirmed by analysts at Goldman Sachs Group Inc. They now have a $116.00 price target on the stock. 2.7%
4/13 Novartis: Recent Selloff Has Presented A Buying Opportunity [Seeking Alpha] 2.4%
3/24 BRIEF-Novartis says Zolgensma helped SMA patients up to 5 years after dosing [Reuters] 2.2%
4/2 New York City hospital worker who caught coronavirus returns to treat patients [FOX News] 2.2%
3/10 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 1.9%
7/17 The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On [The Motley Fool] 4.5%
5/23 Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency 3.6%
8/11 5 Reasons Novartis Shareholders Aren't Shaken [The Motley Fool] 3.4%
8/7 Glancy Prongay & Murray LLP Announces Investigation on Behalf of Novartis AG Investors (NVS) 2.7%
4/4 Novartis AG (NYSE: NVS) had its "buy" rating re-affirmed by analysts at Goldman Sachs Group Inc. They now have a $116.00 price target on the stock. 2.7%
4/13 Novartis: Recent Selloff Has Presented A Buying Opportunity [Seeking Alpha] 2.4%
3/24 BRIEF-Novartis says Zolgensma helped SMA patients up to 5 years after dosing [Reuters] 2.2%
4/2 New York City hospital worker who caught coronavirus returns to treat patients [FOX News] 2.2%
3/10 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 1.9%
TOP News Decliners
2/24
BRIEF-Novartis Announces FDA And EMA Filing Acceptance Of Ofatumumab [Reuters]
-6.9%
4/28 Novartis sales, profits rise in first quarter on COVID-19 buying rush [Reuters (UK)] -3.2%
2/25 Novartis AG (NYSE: NVS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. -3.0%
9/13 BRIEF-Novartis Says Neuronal And Glial Filaments Have Potential To Support Management Of MS Patient [Reuters] -2.8%
4/6 Special Report: Doctors embrace drug touted by Trump for COVID-19, without hard evidence it works [Reuters] -2.7%
3/3 BRIEF-Novartis Receives Health Canada Approval For Mayzent [Reuters] -2.7%
3/20 UPDATE 2-Novartis to donate malaria drug in fight against coronavirus [Reuters] -2.4%
7/11 BRIEF-Novartis, Amgen And Banner Alzheimer's Institute Discontinue Clinical Program With Bace Inhibitor CNP520 [Reuters] -2.3%
3/9 ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS -2.2%
3/20 Novartis to donate malaria drug in fight against coronavirus [Reuters] -2.2%
4/28 Novartis sales, profits rise in first quarter on COVID-19 buying rush [Reuters (UK)] -3.2%
2/25 Novartis AG (NYSE: NVS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. -3.0%
9/13 BRIEF-Novartis Says Neuronal And Glial Filaments Have Potential To Support Management Of MS Patient [Reuters] -2.8%
4/6 Special Report: Doctors embrace drug touted by Trump for COVID-19, without hard evidence it works [Reuters] -2.7%
3/3 BRIEF-Novartis Receives Health Canada Approval For Mayzent [Reuters] -2.7%
3/20 UPDATE 2-Novartis to donate malaria drug in fight against coronavirus [Reuters] -2.4%
7/11 BRIEF-Novartis, Amgen And Banner Alzheimer's Institute Discontinue Clinical Program With Bace Inhibitor CNP520 [Reuters] -2.3%
3/9 ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS -2.2%
3/20 Novartis to donate malaria drug in fight against coronavirus [Reuters] -2.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: